Onc Now
Nuclear medicine has undergone extraordinary transformation over the past decades, and it continues to redefine how cancer is diagnosed and treated. In this episode, Ken Herrmann reflects on his journey into nuclear medicine, the rapid evolution from PET to PET-CT, and the rise of theranostics. He discusses the balance between innovation and evidence, the growing role of multidisciplinary cancer care, and what lies ahead for the field, including the potential impact of AI. This is a forward-looking conversation for clinicians and researchers at every stage of their career.
Apple | Spotify | Amazon Music | Youtube (20 mins)
Speaker bio:
Ken Herrmann is Professor of Nuclear Medicine at the University Hospital Essen in Germany and is internationally recognised as a leading figure in molecular imaging and theranostics. His work focuses on molecular imaging, radioligand therapy, and drug development. Until 2023, he served as Chair of the European Association of Nuclear Medicine (EANM) Oncology & Theranostics Committee.
Timestamps:
00:00 – Introduction
01:07 – His journey into nuclear medicine
02:45 – Impact of nuclear medicine
03:49 – The evolution of his research
05:22 – Theranostics
06:35 – What is the next breakthrough?
08:20 – Balancing innovation with evidence-based practice
09:45 – Multidisciplinary cancer care
11:30 – Biggest challenges in nuclear medicine
13:42 – Future of nuclear medicine
14:58 – Advice to early-career clinicians
16:00 – The potential of AI
17:57 – Three magic wishes for healthcare
Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.
